AI could help doctors personalize treatment for autoimmune hepatitis
NCT ID NCT07378202
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses artificial intelligence to analyze data from 5,000 people with autoimmune hepatitis. The goal is to create a computer model that can predict which patients will respond well to standard therapy within 6 to 12 months. By identifying these patterns early, doctors may be able to adjust treatments sooner and improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Else Kroener Fresenius Center for Digital Health, Technical University Dresden
Dresden, Germany
-
Hannover Medical School
Hanover, 30625, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New blood test may sharpen diagnosis of autoimmune liver disease
- AI may solve tricky liver diagnosis puzzle
- Blood fats and nanoparticles may reveal hidden clues in autoimmune liver disease
- Vegan diet may tame autoimmune hepatitis in kids
- New drug aims to tame autoimmune hepatitis and cut steroid use
- Diet showdown: mediterranean vs. western for autoimmune fatigue